The Delhi High Court ruled that payments from Indian entities to overseas companies are not automatically subject to Indian taxation unless there is a clear nexus to income-producing activities within India.
Reader brief
Through the Reader lens: The Delhi High Court has ruled that payments made by Indian companies to foreign entities are not inherently taxable in India simply because the payer is an Indian resident. In a case involving the Israeli drugmaker Teva, the court found that because the economic activities, rights, and regulatory processes associated with the payment were tied to the US market rather than India, the tax department could not claim the income accrued in India. This decision provides guidance for multinational corporations regarding cross-border payments and limits the tax department's authority to levy taxes based solely on the location of the payer.
What to watch next
- Potential increase in refund claims by foreign companies facing similar tax demands
- Impact on cross-border tax treatment for sectors like technology, telecommunications, and media
- Possible appeal or response by the Indian Income Tax Department
What was said2
Attributed, verbatim. Every quote is checked against the article it came from. One that does not match is not shown.
Dipesh Jain
1 quote“The ruling significantly narrows the ability to tax non-residents merely because an Indian resident makes the payment”
In the article
…that Teva Israel was entitled to a refund of about ₹783 crore, along with applicable interest. The court found that payments received from Ranbaxy did not accrue or arise in India and were linked to the US market. “ The ruling significantly narrows the ability to tax non-residents merely because an Indian resident makes the payment ,” said Dipesh Jain, partner at Economic Laws Practice. The dispute involved payments made by Ranbaxy, now merged with Sun Pharmaceutical Industries Ltd, to Teva Israel under a 2011 settlement relating to the US launch…
Sherry Goyal
1 quote“It’s a sharp rebuke. The AAR was held to have exceeded its mandate, venturing into a roving inquiry into commercial wisdom and branding a genuine settlement a sham, while declining to answer the very taxability question referred to it”
In the article
…enquiry”, the court said the AAR could examine material necessary to answer the question before it, but could not expand the proceedings into a wider review of commercial decisions or foreign contractual disputes. “ It’s a sharp rebuke. The AAR was held to have exceeded its mandate, venturing into a roving inquiry into commercial wisdom and branding a genuine settlement a sham, while declining to answer the very taxability question referred to it ,” said Sherry Goyal, associate partner at DMD Advocates, which represented Teva. The AAR allows taxpayers, including foreign companies, to seek clarity on how specific transactions will be taxed in India. Its rulings…